Lisata Therapeutics, Inc. (LSTA) has a negative trailing P/E of -2.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -38.15%.
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.6 | 0.01 | 3.79 | 0.53 | 80.94% |
| 2017 | 1.5 | -0.01 | 0.70 | 0.00 | - |
| 2018 | -2.1 | 0.01 | 0.91 | 0.00 | - |
| 2019 | -1.3 | -0.08 | 1.24 | 0.00 | - |
| 2020 | -2.7 | 0.04 | 0.68 | 0.00 | - |
| 2021 | -1.7 | 0.29 | 0.50 | 0.00 | - |
| 2022 | -0.2 | -0.01 | 0.20 | 0.00 | - |
| 2023 | -1.1 | 0.01 | 0.46 | 0.00 | - |
| 2024 | -1.2 | 0.18 | 0.84 | 24.82 | - |
| 2025 | -1.0 | 0.05 | 1.09 | 95.05 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-74.81 | $35.28M | $-32.66M | -92.6% |
| 2017 | $38.43 | $0.00 | $22.98M | - |
| 2018 | $-25.03 | $0.00 | $-16.17M | - |
| 2019 | $-29.20 | $0.00 | $-20.1M | - |
| 2020 | $-7.91 | $0.00 | $-8.15M | - |
| 2021 | $-7.45 | $0.00 | $-27.47M | - |
| 2022 | $-10.47 | $121.37M | $-54.23M | -44.7% |
| 2023 | $-2.58 | $0.00 | $-20.84M | - |
| 2024 | $-2.40 | $1M | $-19.99M | -1998.5% |
| 2025 | $-1.91 | $170K | $-16.59M | -9756.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.96 | $-0.96 – $-0.96 | $134.73K | $134.73K – $134.73K | 1 |
| 2027 | $-0.66 | $-0.66 – $-0.66 | $5M | $5M – $5M | 1 |
| 2028 | $-0.98 | $-0.98 – $-0.98 | $3.6M | $3.6M – $3.6M | 1 |
| 2029 | $0.00 | $0.00 – $0.00 | $45M | $45M – $45M | 0 |
